The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
 
Nicole N Scheff
No Relationships to Disclose
 
Marci Lee Nilsen
No Relationships to Disclose
 
Jinhong Li
No Relationships to Disclose
 
Alexandria L Harris
No Relationships to Disclose
 
Andrew Swartz
No Relationships to Disclose
 
Ronan Wenhan Hsieh
No Relationships to Disclose
 
Jennifer Lynn Anderson
No Relationships to Disclose
 
Robert L. Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Achilles Therapeutics; Aduro Biotech; Bicara Therapeutics; Bristol-Myers Squibb; EMD Serono; Everest Clinical Research; F. Hoffmann LaRoche; F. Hoffmann LaRoche; Genocea Biosciences; Hookipa Pharma; Instil Bio; Kowa Research Institute; Lifescience Dynamics; Macrogenics; Merck; Mirati Therapeutics; Novasenta; Numab; OncoCyte; Pfizer; PPD; Rakuten Medical; Sanofi; Seagen; VIR Biotechnology; VIR Biotechnology; Zymeworks; Zymeworks
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro
 
Ashley Menk
No Relationships to Disclose
 
Greg M Delgoffe
No Relationships to Disclose
 
Dan Paul Zandberg
Consulting or Advisory Role - Blueprint Medicines; Macrogenics
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)